- The FDA has signed off Xeris Pharmaceuticals Inc’s (NASDAQ:XERS) Investigational New Drug Application (IND) for its XeriSol levothyroxine (XP-8121) for hypothyroidism.
- Xeris will initiate a Phase 1 study to characterize Pharmacokinetics (PK) and evaluate the safety and tolerability of XP-8121 in healthy participants.
- Price Action: XERS shares are up 21.7% at $2.86 during the premarket session on the last check Thursday.
- Related content: Benzinga’s Full FDA Calendar.
Lipocine Announces LPCN 1144 Met Non-Alcoholic Steatohepatitis Resolution Regulatory Endpoint In Phase 2 LiFT Study
Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of
